Disc Medicine, Inc.

Disc Medicine, Inc., trading under the ticker FSDC, is a clinical-stage biopharmaceutical company focused on hematology that completed its business combination with Foresite Capital Acquisition Corp. IV, a blank-check company sponsored by Foresite Capital Management, LLC. The SPAC conducted its IPO in 2021 targeting the healthcare and life sciences sector. Disc Medicine filed an 8-K current report with the SEC on June 24, 2026, accession number 0001193125-26-281096, disclosing material developments in its ongoing corporate operations. The company is focused on developing therapies for serious blood disorders, operating in the biopharma segment of the healthcare industry. Visit SpacDesk and sign up for full data, filings history, and real-time alerts on FSDC and hundreds of other SPAC transactions.